Sodium/glucose cotransporter
From Proteopedia
(Difference between revisions)
| (6 intermediate revisions not shown.) | |||
| Line 2: | Line 2: | ||
== Function == | == Function == | ||
| - | '''Sodium/glucose cotransporter''' (SGLT) is responsible for glucose absorption across membranes. SGLT1 and SGLT2 which are expressed in different tissues, have similar active sites but differ in their non-active site structures. SGLT1 is responsible of glucose absorption in the small intestine and SGLT2 in kidney<ref>PMID:26125647</ref>. | + | '''Sodium/glucose cotransporter''' (SGLT) is responsible for glucose absorption across membranes. SGLT1 and SGLT2 which are expressed in different tissues, have similar active sites but differ in their non-active site structures. '''SGLT1''' is responsible of glucose absorption in the small intestine and '''SGLT2''' in kidney<ref>PMID:26125647</ref>. |
== Disease == | == Disease == | ||
| Line 14: | Line 14: | ||
== Structural highlights == | == Structural highlights == | ||
| - | The drug | + | The drug Dapagliflozin contains a <scene name='10/1042600/Cv/5'>glucose moiety which stacks against residue Y290</scene> of SGLT2. The <scene name='10/1042600/Cv/6'>glucose moiety forms multiple H-bonds</scene> to SGLT2<ref>PMID:38057552</ref>. Water molecule is shown as red sphere. |
| + | See also: | ||
| + | *[[Canagliflozin]] | ||
| + | *[[Dapagliflozin]] | ||
| + | *[[Empagliflozin]] | ||
==3D structures of sodium/glucose cotransporter== | ==3D structures of sodium/glucose cotransporter== | ||
Current revision
| |||||||||||
References
- ↑ Poulsen SB, Fenton RA, Rieg T. Sodium-glucose cotransport. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):463-9. PMID:26125647 doi:10.1097/MNH.0000000000000152
- ↑ Dominguez Rieg JA, Rieg T. What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition. Diabetes Obes Metab. 2019 Apr;21 Suppl 2(Suppl 2):43-52. PMID:31081587 doi:10.1111/dom.13630
- ↑ Jasleen B, Vishal GK, Sameera M, Fahad M, Brendan O, Deion S, Pemminati S. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk. Cureus. 2023 Jan 18;15(1):e33939. PMID:36819350 doi:10.7759/cureus.33939
- ↑ Hiraizumi M, Akashi T, Murasaki K, Kishida H, Kumanomidou T, Torimoto N, Nureki O, Miyaguchi I. Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter. Nat Struct Mol Biol. 2024 Jan;31(1):159-169. PMID:38057552 doi:10.1038/s41594-023-01134-0
